This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
by Zacks Equity Research
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 66.67% and 42.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 14.29% and 6.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Verve Therapeutics (VERV) delivered earnings and revenue surprises of 13.24% and 27.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -100% and 2.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
by Zacks Equity Research
Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to gain from growth in Emerging Markets and Europe and expansion of business activities in Japan, offset by declines in North America.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 39.13% and 6.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
by Zacks Equity Research
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
by Zacks Equity Research
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy From a Rebounding Industry
by Kinjel Shah
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 5.66% and 20.16%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.